CARL ZEISS MEDITEC AG - BR (AFX.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:AFX - DE0005313704 - Common Stock
40.3 EUR
+0.06 (+0.15%)
Taking everything into account, AFX scores 5 out of 10 in our fundamental rating. AFX was compared to 65 industry peers in the Health Care Equipment & Supplies industry. AFX has an average financial health and profitability rating. AFX is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
AFX had positive earnings in the past year.
In the past year AFX had a positive cash flow from operations.
Each year in the past 5 years AFX has been profitable.
Each year in the past 5 years AFX had a positive operating cash flow.
1.2 Ratios
AFX has a Return On Assets (4.15%) which is in line with its industry peers.
AFX has a Return On Equity (6.67%) which is comparable to the rest of the industry.
The Return On Invested Capital of AFX (5.79%) is comparable to the rest of the industry.
AFX had an Average Return On Invested Capital over the past 3 years of 7.11%. This is below the industry average of 9.71%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.15% | ||
| ROE | 6.67% | ||
| ROIC | 5.79% |
ROA(3y)6.33%
ROA(5y)7.85%
ROE(3y)9.62%
ROE(5y)11.54%
ROIC(3y)7.11%
ROIC(5y)9.66%
1.3 Margins
AFX has a Profit Margin (6.34%) which is comparable to the rest of the industry.
In the last couple of years the Profit Margin of AFX has declined.
AFX has a Operating Margin (10.03%) which is comparable to the rest of the industry.
AFX's Operating Margin has declined in the last couple of years.
AFX has a Gross Margin (52.76%) which is in line with its industry peers.
AFX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.03% | ||
| PM (TTM) | 6.34% | ||
| GM | 52.76% |
OM growth 3Y-21.67%
OM growth 5Y-5.49%
PM growth 3Y-25.69%
PM growth 5Y-7.11%
GM growth 3Y-3.8%
GM growth 5Y-1.12%
2. Health
2.1 Basic Checks
AFX has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, AFX has about the same amount of shares outstanding.
Compared to 5 years ago, AFX has less shares outstanding
The debt/assets ratio for AFX has been reduced compared to a year ago.
2.2 Solvency
AFX has an Altman-Z score of 3.46. This indicates that AFX is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of AFX (3.46) is better than 66.15% of its industry peers.
The Debt to FCF ratio of AFX is 4.41, which is a neutral value as it means it would take AFX, 4.41 years of fcf income to pay off all of its debts.
AFX has a Debt to FCF ratio (4.41) which is in line with its industry peers.
AFX has a Debt/Equity ratio of 0.27. This is a healthy value indicating a solid balance between debt and equity.
AFX has a Debt to Equity ratio (0.27) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | 4.41 | ||
| Altman-Z | 3.46 |
ROIC/WACC0.86
WACC6.72%
2.3 Liquidity
AFX has a Current Ratio of 2.35. This indicates that AFX is financially healthy and has no problem in meeting its short term obligations.
AFX has a better Current ratio (2.35) than 69.23% of its industry peers.
A Quick Ratio of 1.44 indicates that AFX should not have too much problems paying its short term obligations.
With a decent Quick ratio value of 1.44, AFX is doing good in the industry, outperforming 72.31% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.35 | ||
| Quick Ratio | 1.44 |
3. Growth
3.1 Past
AFX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -19.90%.
Measured over the past 5 years, AFX shows a small growth in Earnings Per Share. The EPS has been growing by 3.28% on average per year.
Looking at the last year, AFX shows a small growth in Revenue. The Revenue has grown by 7.82% in the last year.
The Revenue has been growing by 10.78% on average over the past years. This is quite good.
EPS 1Y (TTM)-19.9%
EPS 3Y-21.2%
EPS 5Y3.28%
EPS Q2Q%-14.49%
Revenue 1Y (TTM)7.82%
Revenue growth 3Y5.39%
Revenue growth 5Y10.78%
Sales Q2Q%8.27%
3.2 Future
The Earnings Per Share is expected to grow by 20.13% on average over the next years. This is a very strong growth
AFX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.97% yearly.
EPS Next Y27.78%
EPS Next 2Y25.05%
EPS Next 3Y26.27%
EPS Next 5Y20.13%
Revenue Next Year4.86%
Revenue Next 2Y6.03%
Revenue Next 3Y6.88%
Revenue Next 5Y6.97%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 25.03, AFX can be considered very expensive at the moment.
Based on the Price/Earnings ratio, AFX is valued a bit cheaper than the industry average as 67.69% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 26.50. AFX is around the same levels.
With a Price/Forward Earnings ratio of 19.59, AFX is valued on the expensive side.
Compared to the rest of the industry, the Price/Forward Earnings ratio of AFX indicates a somewhat cheap valuation: AFX is cheaper than 61.54% of the companies listed in the same industry.
AFX is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 23.93, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.03 | ||
| Fwd PE | 19.59 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, AFX is valued a bit cheaper than 76.92% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, AFX is valued a bit cheaper than the industry average as 69.23% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 27.05 | ||
| EV/EBITDA | 11.75 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
AFX's earnings are expected to grow with 26.27% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.9
PEG (5Y)7.63
EPS Next 2Y25.05%
EPS Next 3Y26.27%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 1.38%, AFX has a reasonable but not impressive dividend return.
AFX's Dividend Yield is a higher than the industry average which is at 1.03.
Compared to the average S&P500 Dividend Yield of 1.87, AFX is paying slightly less dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.38% |
5.2 History
The dividend of AFX decreases each year by -1.59%.
Dividend Growth(5Y)-1.59%
Div Incr Years1
Div Non Decr Years4
5.3 Sustainability
AFX pays out 37.19% of its income as dividend. This is a sustainable payout ratio.
DP37.19%
EPS Next 2Y25.05%
EPS Next 3Y26.27%
FRA:AFX (12/23/2025, 7:00:00 PM)
40.3
+0.06 (+0.15%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners25.58%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap3.60B
Revenue(TTM)2.23B
Net Income(TTM)141.22M
Analysts73.64
Price Target55.56 (37.87%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.38% |
Yearly Dividend0.6
Dividend Growth(5Y)-1.59%
DP37.19%
Div Incr Years1
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-21.46%
Min EPS beat(2)-33.88%
Max EPS beat(2)-9.05%
EPS beat(4)1
Avg EPS beat(4)-16.59%
Min EPS beat(4)-36.67%
Max EPS beat(4)13.25%
EPS beat(8)4
Avg EPS beat(8)-3.62%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.89%
Min Revenue beat(2)-1.14%
Max Revenue beat(2)2.92%
Revenue beat(4)3
Avg Revenue beat(4)1.59%
Min Revenue beat(4)-1.14%
Max Revenue beat(4)3.76%
Revenue beat(8)5
Avg Revenue beat(8)-0.32%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0.25%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-0.61%
EPS NY rev (3m)-8.19%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)-0.17%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.03 | ||
| Fwd PE | 19.59 | ||
| P/S | 1.62 | ||
| P/FCF | 27.05 | ||
| P/OCF | 17.18 | ||
| P/B | 1.7 | ||
| P/tB | 7.45 | ||
| EV/EBITDA | 11.75 |
EPS(TTM)1.61
EY4%
EPS(NY)2.06
Fwd EY5.1%
FCF(TTM)1.49
FCFY3.7%
OCF(TTM)2.35
OCFY5.82%
SpS24.91
BVpS23.66
TBVpS5.41
PEG (NY)0.9
PEG (5Y)7.63
Graham Number29.28
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.15% | ||
| ROE | 6.67% | ||
| ROCE | 7.81% | ||
| ROIC | 5.79% | ||
| ROICexc | 5.89% | ||
| ROICexgc | 14.08% | ||
| OM | 10.03% | ||
| PM (TTM) | 6.34% | ||
| GM | 52.76% | ||
| FCFM | 5.98% |
ROA(3y)6.33%
ROA(5y)7.85%
ROE(3y)9.62%
ROE(5y)11.54%
ROIC(3y)7.11%
ROIC(5y)9.66%
ROICexc(3y)7.22%
ROICexc(5y)9.75%
ROICexgc(3y)13.97%
ROICexgc(5y)15.82%
ROCE(3y)9.59%
ROCE(5y)13.04%
ROICexgc growth 3Y-8.4%
ROICexgc growth 5Y5.55%
ROICexc growth 3Y-23.03%
ROICexc growth 5Y-5.34%
OM growth 3Y-21.67%
OM growth 5Y-5.49%
PM growth 3Y-25.69%
PM growth 5Y-7.11%
GM growth 3Y-3.8%
GM growth 5Y-1.12%
F-Score6
Asset Turnover0.65
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | 4.41 | ||
| Debt/EBITDA | 1.61 | ||
| Cap/Depr | 60.61% | ||
| Cap/Sales | 3.44% | ||
| Interest Coverage | 10.38 | ||
| Cash Conversion | 60% | ||
| Profit Quality | 94.37% | ||
| Current Ratio | 2.35 | ||
| Quick Ratio | 1.44 | ||
| Altman-Z | 3.46 |
F-Score6
WACC6.72%
ROIC/WACC0.86
Cap/Depr(3y)109.66%
Cap/Depr(5y)110.76%
Cap/Sales(3y)5.42%
Cap/Sales(5y)4.92%
Profit Quality(3y)64.92%
Profit Quality(5y)71.29%
High Growth Momentum
Growth
EPS 1Y (TTM)-19.9%
EPS 3Y-21.2%
EPS 5Y3.28%
EPS Q2Q%-14.49%
EPS Next Y27.78%
EPS Next 2Y25.05%
EPS Next 3Y26.27%
EPS Next 5Y20.13%
Revenue 1Y (TTM)7.82%
Revenue growth 3Y5.39%
Revenue growth 5Y10.78%
Sales Q2Q%8.27%
Revenue Next Year4.86%
Revenue Next 2Y6.03%
Revenue Next 3Y6.88%
Revenue Next 5Y6.97%
EBIT growth 1Y14.86%
EBIT growth 3Y-17.44%
EBIT growth 5Y4.69%
EBIT Next Year73.64%
EBIT Next 3Y32.77%
EBIT Next 5Y23.51%
FCF growth 1Y40.11%
FCF growth 3Y7.85%
FCF growth 5Y-0.04%
OCF growth 1Y-15.15%
OCF growth 3Y3.7%
OCF growth 5Y3.29%
CARL ZEISS MEDITEC AG - BR / AFX.DE FAQ
What is the fundamental rating for AFX stock?
ChartMill assigns a fundamental rating of 5 / 10 to AFX.DE.
Can you provide the valuation status for CARL ZEISS MEDITEC AG - BR?
ChartMill assigns a valuation rating of 5 / 10 to CARL ZEISS MEDITEC AG - BR (AFX.DE). This can be considered as Fairly Valued.
Can you provide the profitability details for CARL ZEISS MEDITEC AG - BR?
CARL ZEISS MEDITEC AG - BR (AFX.DE) has a profitability rating of 4 / 10.
What is the valuation of CARL ZEISS MEDITEC AG - BR based on its PE and PB ratios?
The Price/Earnings (PE) ratio for CARL ZEISS MEDITEC AG - BR (AFX.DE) is 25.03 and the Price/Book (PB) ratio is 1.7.
What is the financial health of CARL ZEISS MEDITEC AG - BR (AFX.DE) stock?
The financial health rating of CARL ZEISS MEDITEC AG - BR (AFX.DE) is 6 / 10.